<DOC>
	<DOCNO>NCT00229138</DOCNO>
	<brief_summary>This study investigate safety , tolerability efficacy EC-MPS tacrolimus reference reduce level . This study take account safety aspect decrease renal toxicity reduce overall exposure tacrolimus .</brief_summary>
	<brief_title>Efficacy Safety Enteric-Coated Mycophenolate Sodium ( EC-MPS ) Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female kidney transplantation patient , 18 70 year age , receive primary cadaveric , live unrelated , nonHLA identical living relate donor kidney . The renal cold ischemic time ( CIT ) must &lt; 30 hour The age donor must 10 65 year Exclusion Criteria Patients previously receive organ transplant Patients recipient multiple organ transplant Recipients non heartbeating donor organ ABO incompatibility donor Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>De novo kidney recipient ,</keyword>
	<keyword>EC-MPS ,</keyword>
	<keyword>tacrolimus ,</keyword>
	<keyword>efficacy ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>glomerular filtration rate</keyword>
	<keyword>Treatment de novo kidney recipient</keyword>
</DOC>